Research | Open | Published:
A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia
Acta Neuropathologica Communicationsvolume 6, Article number: 39 (2018)
Degeneration of noradrenergic locus coeruleus neurons occurs during the prodromal phase of Parkinson’s disease and contributes to a variety of non-motor symptoms, e.g. depression, anxiety and REM sleep behavior disorder. This study was designed to establish the first locus coeruleus α-synucleinopathy mouse model, which should provide sufficient information about the time-course of noradrenergic neurodegeneration, replicate cardinal histopathological features of the human Parkinson’s disease neuropathology and finally lead to robust histological markers, which are sufficient to assess the pathological changes in a quantitative and qualitative way. We show that targeted viral vector-mediated overexpression of human mutant A53T-α-synuclein in vivo in locus coeruleus neurons of wild-type mice resulted in progressive noradrenergic neurodegeneration over a time frame of 9 weeks. Observed neuronal cell loss was accompanied by progressive α-synuclein phosphorylation, formation of proteinase K-resistant α-synuclein-aggregates, accumulation of Ubi-1- and p62-positive inclusions in microglia and induction of progressive micro- and astrogliosis. Apart from this local pathology, abundant α-synuclein-positive axons were found in locus coeruleus output regions, indicating rapid anterograde axonal transport of A53T-α-synuclein. Taken together, we present the first model of α-synucleinopathy in the murine locus coeruleus, replicating essential morphological features of human Parkinson’s disease pathology. This new model may contribute to the research on prodromal Parkinson’s disease, in respect to pathophysiology and the development of disease-modifying therapy.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder  characterized by progressive degeneration of dopaminergic (DA) substantia nigra (SN) neurons and their striatal axon terminals [40, 68]. One characteristic neuropathological hallmark of PD are intracytoplasmic eosinophilic inclusions, the so-called Lewy bodies, which develop in specific brain regions in a spatio-temporal pattern and consist predominantly of misfolded α-synuclein (aSYN) [11, 83]. The finding that duplications, triplications or missense mutations (e.g. A53T, A30P or G46 L) of the aSYN gene (SNCA) cause familial forms of PD [46, 67] has justified the assumption that aSYN plays a crucial role in the pathogenesis of PD.
Only within the last 20 years it is accepted that PD cannot solely be understood as a disease associated with the degeneration of DA SN neurons, as the PD pathology involves the central, peripheral, autonomic and enteric nervous system [11, 12, 16, 79, 95]. The degeneration of DA SN neurons and the onset of motor dysfunction are preceded by a latency of several years, if not decades, in which the PD pathology develops in brain regions outside the DA SN. This phase, termed prodromal PD, is clinically characterized by the occurrence of certain non-motor symptoms, e.g. hyposmia, constipation, depression and idiopathic REM sleep behavior disorder [31, 53, 84]. Since the prodromal phase is seen as the ideal time window for applying disease-modifying therapy [60, 92], it is of high importance to establish animal models, which allow testing of new and future therapeutic approaches on brain structures that are affected during prodromal PD. The noradrenergic locus coeruleus (LC), a monoaminergic nucleus located in the pontine brainstem [3, 8], plays a crucial role during the prodromal phase of PD and represents therefore an ideal brain structure for such in-depth characterization in an experimental animal model . Dysfunction and degeneration of neurons in the LC region are associated with several of the above listed non-motor symptoms, including depression, signs of reduced arousal, anxiety and REM sleep behavior disorder (RBD) [17, 27, 93]. Neuropathological analysis of human PD brain samples revealed up to 80% LC neuronal cell loss in PD patients, thereby exceeding the degree of SN neurodegeneration in the same individuals [58, 99]. Moreover, experimental evidence indicates that toxin-induced LC cell loss sensitized DA SN neurons for neurodegeneration [9, 22], whereas noradrenergic hyperinnervation resulted in neuroprotective effects . This data implies that LC neurodegeneration itself plays a double role by firstly being responsible for several non-motor symptoms and secondly for accelerating the progression of PD at the nigral level . LC cells exhibit a common at-risk phenotype compared to other neuronal populations such as the DA nigral neurons and the cholinergic neurons of the dorsal motor nucleus of the vagal nerve which undergo neurodegeneration in PD [6, 78]. LC neurons integrate information from a broad range of different brain regions and broadcast information with extensively branched and thinly myelinated axons throughout the complete neuroaxis [8, 75]. Furthermore, they exhibit an intrinsic pacemaking activity, generating action potentials continuously  thereby raising their basal metabolic stress level .
In this study, we have characterized the first model of α-synucleinopathy in the murine LC. We show that targeted viral vector-mediated overexpression of human mutant A53T-aSYN in vivo in LC neurons of wild-type mice resulted in progressive LC neurodegeneration over a time frame of 9 weeks. Observed LC cell loss was accompanied by prominent and over time increasing micro- and astrogliosis. In addition, our data revealed accumulation of phosphorylated aSYN, progressive aggregation of aSYN as demonstrated by proteinase K-resistant aSYN aggregates and Ubi-1- and p62-positive inclusions comparable with findings from human PD samples. Co-staining with different cellular markers revealed that the p62- and Ubi-1-positive aggregates were found exclusively in microglial cells, while being absent in neurons, astrocytes and oligodendrocytes. Beside this local LC pathology, we observed abundant aSYN-positive axons in a high number of LC output regions, indicating rapid anterograde axonal transport of the human aSYN. In conclusion, our new murine LC model replicated cardinal morphological features of human PD pathology.
Materials and methods
A total of 70 wild-type male C57BL/6 N mice (Charles River, Sulzfeld, Germany), 8 weeks old at the beginning of the experiment, were used. Mice were housed in individually ventilated cages with ad libitum access to food and water under a 12 h/12 h light-dark cycle. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted (Regierungspräsidium Giessen, Germany V54–19 c 20 15 h 01 MR 20/15 Nr. 66/2015).
Recombinant adeno-associated viral (rAAV) vectors and stereotactic injection
Two different recombinant adeno-associated viral (rAAV) vectors of a mixed 1/2 serotype were used to overexpress human mutant-A53T-aSYN (rAAV1/2-CMV/CBA-human-A53T-aSYN-WPRE-BGH-pA (rAAV1/2-A53T-aSYN); viral titer 5.1 × 1012 gp/ml, purchased from GeneDetect) or luciferase (rAAV1/2-CMV/CBA-luciferase-WPRE-BGH-pA (rAAV1/2-Luc), viral titer 5.0 × 1012 gp/ml, purchased from GeneDetect). Each of the two vectors was driven by a chicken beta actin (CBA) promoter combined with a cytomegalovirus (CMV) immediate early enhancer sequence and a woodchuck post-transcriptional regulatory element (WPRE) to assess a high transcription rate [38, 44]. For stereotactic delivery of the rAAV vectors, mice were anesthetized with 100 mg/kg ketamine and 5 mg/kg xylazine via intraperitoneal injection. A volume of 1.25 μl of rAAV1/2-A53T-aSYN or rAAV1/2-Luc was stereotactically injected in the right LC region using a microinjector (UltraMicro Pump UMP3, World Precision Instruments) with a velocity of 125 nl/min based on the following coordinates: ML − 0.9 mm, AP -5.4 mm and DV -3.65 mm relative to Bregma .
Mice were sacrificed through transcardial perfusion with 0.1 M phosphate-buffered saline (PBS) for 5 min followed by 4% ice-cold paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) (pH 7.4) for 5 min using a supply pump at a rate of 10 ml/min. Brains were carefully removed and post-fixed in 4% PFA for 3 days and then transferred to 30% sucrose solution for 3 days for cryoprotection. Brains were cut into 20 μm thick coronal sections using a cryostat microtome (Leica CM3050 S, Nussloch, Germany). Sections were then stored at 4 °C in cryoprotect-solution (1:1:3 volume ratio of ethylenglycol, glycerol and 0.1 M PB) until further processing.
Immunohistochemistry with 3,3-diaminobenzidine (DAB)
Free-floating sections containing the LC/SN region were washed in 0.1 M PB and quenched with 3% H2O2 and 10% methanol for 15 min. After a second wash, sections were blocked in 5% normal donkey serum with 0.3% Triton X-100 in 0.1 M PB for 1 h before incubating them overnight with primary antibodies against TH, p-aSYN, Ubi-1 or p62 (Table 1) at 4 °C in the same blocking solution. On the second day, sections were washed in 0.1 M PB for 20 min and then incubated with the appropriate biotinylated secondary antibody (Table 1) for 1 h, followed by incubation in avidin-biotin-peroxidase solution (ABC Elite, Vector Laboratories) for 1 h before initiating the color reaction with 5% DAB (Serva), diluted in 0.1 M PB with 0.02% H2O2. All DAB-stained sections were mounted, dried, counterstained with cresyl-violet and coverslipped with mounting gel (Corbit-Balsam, Eukitt). Brightfield images were acquired using an AxioImager M2 microscope (Zeiss) equipped with an Axiocam 506 color camera (Zeiss).
Sections were washed in 0.1 M PB, then blocked in 10% normal donkey serum with 0.3% Triton X-100 in 0.1 M PB for 1 h before incubating them with primary antibodies (Table 1) at 4 °C in the same blocking solution overnight. On the second day, sections were washed in 0.1 M PB containing 0.3% Triton X-100 and then incubated with fluorophore-conjugated, species-specific secondary antibodies (Table 1) for 2 h at room temperature in 0.1 M PB containing 0.3% Triton X-100 and 10% normal donkey serum. Before mounting sections were washed for 25 min in 0.1 M PB containing 0.3% Triton X-100. Exceptions from this general protocol were made for staining luciferase, p-aSYN, IbA1 and Olig2, where after primary antibody incubation a biotinylated species-specific secondary antibody was used to further improve signal to noise by conjugation with streptavidin. Images were acquired using an AxioImager M2 microscope (Zeiss) equipped with an ORCA-Flash4.0 LT CMOS camera (Hamamatsu C11440-42 U). For confocal images, a TCS SP8 microscope (Leica) was used. Images were processed with FIJI image software  to enhance signal-to-noise. Image data for 3D reconstructions were obtained with a Zeiss Spinning Disc Microscope (Axio Observer Z1) equipped with an Axiocam MRm (Zeiss) and an Evolve 512 EMCCD Camera (Photometrics) and post-processed with ZEN 2012 software (Zeiss).
Proteinase K treatment
To analyze the formation of insoluble aggregates, sections were digested with Proteinase K (PK) using a modified protocol described elsewhere [21, 86]. 20 μm thick sections with 120 μm interslice distance containing the complete LC region were washed in 0.1 M PB and subsequently digested in 0.1 M PB containing 0.3% Triton X-100 and 12 μg/ml PK (Cat. No. 4333793, Invitrogen) at 65 °C for 10 min. To visualize insoluble aggregates, digested sections were double stained against human aSYN, p62, Ubi-1 or luciferase in combination with TH (Table 1), following the fluorescence staining protocol described above. Complete absence of TH immunoreactivity served as an indicator for successful PK digestion, thus sections in which TH immunoreactivity was still visible were excluded from analysis implicating an incomplete protein digestion. Images were acquired using an AxioImager M2 microscope (Zeiss) equipped with an ORCA-Flash4.0 LT CMOS camera (Hamamatsu C11440-42 U).
To quantify TH-positive LC and SN neurons, the optical fractionator workflow (StereoInvestigator version 9, MicroBrightField Biosciences) was used. Therefore, tissue sections were stained against TH with DAB and counterstained with cresyl-violet as described above. To quantify LC cell numbers, five sections per animal containing the complete rostro-caudal extent of the LC region, separated by 120 μm, were selected. Contours including all TH-positive neurons of the LC were drawn, excluding neurons of the SubLC region. For quantification of TH-positive SN neurons, seven sections separated by 240 μm covering the complete caudo-rostral extent of the SN were used. Contours were drawn based on the cytoarchitectonic distribution of SN neurons  including SN pars compacta but excluding SN pars reticulata or ventral tegmental area neurons. Parameters used for counting were: grid size 100 × 100 μm, counting frame 85 × 85 μm, and 2 μm guard zones.
Quantification of reactive micro- and astrogliosis
Triple immunofluorescence stainings were performed to visualize astro- and microgliosis using antibodies directed against GFAP for astroglia, IbA1 for microglia and TH to label LC neurons (Table 1). To quantify signs of reactive gliosis, we evaluated 5 LC sections of 6 animals per time point by measuring the optical density (OD) of the injected versus the non-injected side using FIJI. First, greyscale images were converted to 8 bit and the LC region was outlined with a rectangular contour (1200px x 800px). Then, OD was measured and lastly a background correction was performed by subtracting the mean background signal for every section. The background corrected OD values of all 5 sections of the injected side were summed and compared to the summed value of the non-injected side.
Quantification of S129-phosphorylated aSYN
To analyze the degree of p-aSYN, a triple immunofluorescence staining against p-aSYN, human aSYN and TH was performed (Table 1). Five sections of 4 animals per time point, containing the complete rostro-caudal extent of the LC region, were selected for analysis. First, images were converted to 8 bit before making them binary. By using a preset intensity threshold, pixels were given either an intensity value of 255 (when positive for p-aSYN) or 0 (when negative for p-aSYN). The resulting p-aSYN signal intensity value was then divided by the area positive for non-phosphorylated aSYN. This ratio was calculated for all five sections and averaged per animal.
Quantification of aSYN transport
Seven coronal sections (Bregma: + 4.28, + 2.86, + 1.18, + 0.38, − 0.58, − 3.16 and − 7.56) covering the complete mouse brain were stained against human aSYN (Syn 211) or Luc (Table 1) and the degree of aSYN accumulation was assessed by scoring human aSYN positive axons/cell bodies as follows: – no positive axons; + sparse (few positive axons); ++ mild (more positive axons); +++ moderate (many positive axons, covering almost the complete brain region) and ++++ severe pathology (large number of positive axons densely covering the complete brain region). (+) describes an intermediate state. Six animals per time point were analyzed and the scores for each brain region were averaged.
In general, all data values are expressed as mean ± SEM or mean ± min/max. Differences were considered significant at p < 0.05. Multiple comparisons were made by one-way or two-way ANOVA analysis followed by Tukey’s or Sidak’s multiple comparisons test. To calculate correlations, Pearson’s correlation coefficient with 95% confidence interval was used. All statistical analyses were performed using GraphPad Prism version 7.00 (GraphPad Software, La Jolla California USA). Figures were created with Adobe Illustrator version 21.1 (Adobe Systems).
rAAV vector-mediated overexpression of human A53T-aSYN in LC neurons
To determine whether and in which time frame aSYN overexpression induces PD-like pathology in LC neurons we chose to overexpress human mutant A53T-aSYN by injecting rAAV1/2-A53T-aSYN [38, 44] unilaterally in the right LC region of wild-type mice (Fig. 1a, b). To verify that the resulting cellular effects were attributable to the aSYN protein itself, luciferase (Luc) was used as a control protein. To investigate time-dependent effects, animals were consecutively sacrificed after 3 days, 1, 3, 6 and 9 weeks (Fig. 1b).
By analyzing the first set of animals 3 days after viral injection, we confirmed that both vectors entered LC neurons equally (Fig. 1c, d), resulting in infection rates of 85.17 ± 2.53% for A53T-aSYN and 83.87 ± 3.31% for Luc (unpaired t-test, p = 0.77) (Fig. 1d). Double immunofluorescence stainings against TH and human aSYN or TH and Luc (Fig. 1e, f) revealed that both vectors induced protein expression already at this early time point with similar strength (A53T-aSYN 59.89 ± 2.95% and Luc 54.39 ± 3.57%, unpaired t-test, p = 0.30). Protein expression was mainly restricted to the LC covering the whole nucleus (Fig. 1g, h). In addition, a variable number of immuno-reactive cells were observed in the adjacent regions (ncl. Parabrachialis, Barrington’s nucleus, mesencephalic trigeminal nucleus and vestibular nuclei) (Fig. 1g). In LC neurons, cell bodies, as well as axons and dendrites were robustly labeled, indicating strong protein expression. Similar findings were observed for rAAV1/2-Luc injected animals. Notably, there was no aSYN or Luc signal in LC cells on the non-injected side at any time point (Fig. 1g). This allowed us to use the non-injected (left) side as an internal control.
A53T-aSYN overexpression causes LC neurodegeneration
In the first set of experiments, the extent of aSYN induced LC cell loss was assessed with unbiased stereological quantification of TH-positive LC cells 1, 3, 6 and 9 weeks after viral vector delivery. In the A53T-aSYN group, significant degeneration of TH-positive LC cells was measured already 3 weeks post-injection, with 15.86 ± 2.09% cell loss compared to control side. Neurodegeneration increased progressively reaching 34.84 ± 3.39% after 6 weeks and 56.25 ± 5.19% after 9 weeks (Fig. 2a, b). Cell loss was homogenously distributed over the complete rostro-caudal extent of the LC. No cellular pathology was observed in the Luc control group at any investigated time point, confirming that neither the viral vector nor overexpression of a cytoplasmic protein was able to induce neurodegeneration in our model (Fig. 2a, b).
Moreover, immunofluorescent TH-stainings and subsequent confocal imaging revealed that A53T-aSYN, but not Luc overexpression was accompanied by qualitative changes of neuronal morphology, including dystrophic axons and pyknotic perikarya (Fig. 2c).
Accumulation of phosphorylated-aSYN in the LC region
Phosphorylation of aSYN at amino acid serine 129 (p-aSYN) is a commonly observed phenomenon in human PD brain tissue and in animal models artificially overexpressing aSYN [1, 25, 52, 72, 98]. In these models, the S129 phosphorylation is frequently used as an indicator for aSYN aggregation. In our current study, we measured the signal intensity of p-aSYN systematically via double immunofluorescence stainings for TH and p-aSYN. Our data revealed that A53T-aSYN overexpression led to strong and progressive phosphorylation of aSYN in LC neurons (Fig. 3a, b). Accumulation of p-aSYN started early with positive cells being observable already 1 week post-injection, reaching highest levels at the latest time point. Generally, the p-aSYN signal was homogenously distributed in the cytoplasm of TH-positive LC cells. In addition, robust labeling of the nucleus was observed (Fig. 3d, e). To exclude the possibility of non-specific antibody labeling we analyzed rAAV-Luc injected animals, which showed no signal for p-aSYN at any time point (Fig. 3d, e). Next, we wanted to quantify if the degree of phosphorylation correlated with the degree of noradrenergic cell loss. Therefore, the p-aSYN signal intensity values were plotted and correlated with the percentage of LC cell loss (Fig. 3c). The strong correlation (r = 0.67, p < 0.05) indicates that the degree of aSYN phosphorylation can be used as a predictor of aSYN toxicity in our model.
Formation of proteinase K (PK)-resistant, p62-, Ubi-1- and aSYN-positive aggregates
Lewy bodies in human PD brain tissue are characterized by immunoreactivity for insoluble (PK-resistant) aSYN, but also for a variety of other proteins, such as ubiquitin-1 (Ubi-1) and p62/SQSTM1/sequestosome-1 (p62) [33, 47]. Both of the latter proteins are implicated in the cellular clearance of aSYN. Occurrence of PK-resistant Ubi-1-positive aggregates indicates an overburdened proteasomal clearing system, while dysfunction of the lysosomal system can result in accumulation of p62-positive aggregates . To test whether proteasomal and/or lysosomal clearance might be impaired in our model, we systematically screened A53T-aSYN and Luc overexpressing animals for p62- and Ubi-1-immunoreactivity. A53T-aSYN, but not Luc injected mice showed abundant p62- and Ubi-1-positive aggregates starting 3 weeks after viral vector delivery reaching highest numbers at the latest time point (Fig. 4a, b). Ubi-1-, as well as p62-positive inclusions appeared as small circular objects surrounding the nuclei of the cells (Fig. 4b) and were restricted to the ipsilateral side of injection. As in the previous experiments most of the p-aSYN signal was seen in TH-positive neurons (Fig. 3a, d), we expected a high rate of co-localization for p62 and Ubi-1 with the LC marker TH. However, the majority of p62 and Ubi-1 immunoreactivity was located next to TH-positive LC cells, suggesting that other cells are involved in this process (Fig. 4a). To elucidate in which cell type the p62-positive aggregates were located, double immunofluorescence stainings for p62 with MAP2 (neuronal marker), Olig2 (oligodendroglial marker), GFAP (astrocytic marker) or IbA1 (microglial marker) were performed. While p62 did not co-localize with MAP2 (Fig. 5a), Olig2 (Fig. 5b) or GFAP (Fig. 5c), we observed clear co-localization with IbA1 (Fig. 5d), indicating that the p62-positive inclusions were located in microglial cells. Moreover, we further confirmed that Ubi-1-positive aggregates were also located in microglia (Fig. 5e). Double immunofluorescence stainings for IbA1 and aSYN (Syn211) (Fig. 5f, arrow) and GFAP and aSYN (Syn211) (Fig. 5g, arrow) revealed that microglia, as well as astroglia exhibited human aSYN after 3 weeks of aSYN overexpression.
Next, we aimed to investigate if the observed p62- and Ubi-1-positive inclusions indeed consisted of insoluble aggregated proteins. Since PK resistance is accepted as a valid marker for the formation of insoluble aggregates in human PD samples and animal models [5, 38, 86], we digested tissue samples of A53T-aSYN and Luc injected mice of all time points with PK. As a result, numerous PK-resistant insoluble aggregates positive for p62, Ubi-1 and aSYN were found in A53T-aSYN injected mice (Fig. 4c). Notably, PK-resistant aSYN aggregates had the same shape and size as Ubi-1- and p62-inclusions. Further, all three kinds of aggregates started to appear 3 weeks after initiation of A53T-aSYN overexpression and were restricted to the site of viral injection. PK digestion and subsequent analysis of rAAV-Luc injected animals revealed no signal for aSYN, p62, Ubi-1 or Luc in any analyzed section.
Targeted α-synucleinopathy induces reactive micro- and astrogliosis in the LC region
Microglia activation and reactive astrocytes have been observed by respective PET imaging in human prodromal and manifest PD patients [26, 63], post-mortem PD brain samples [56, 62] and aSYN animal models [4, 87, 88]. Most of the studies using animal models focused on the impact of microglia activation following nigrostriatal degeneration. In the current study, we aimed to investigate whether a focally induced α-synucleinopathy in the LC region would lead to reactive micro- and astrogliosis. Therefore, a triple immunofluorescence staining for IbA1 (microglial marker), GFAP (astroglial marker) and TH was carried out and the intensity of fluorescence signal was quantified (Fig. 6a-c). Already 3 weeks of A53T-aSYN overexpression were sufficient to induce a 3.5-fold increase of astroglial signal intensity in the injected LC region compared to Luc control. The astrogliosis further progressed up to a 6-fold increase after 9 weeks (Fig. 6b). Simultaneously, a 3-fold signal increase for microglia was measured after 3 weeks of A53T-aSYN overexpression and a 5-fold increase after 9 weeks, compared to Luc (Fig. 6c). 3D reconstructed high magnification confocal images revealed a dense glial network in A53T-aSYN overexpressing animals, in which the remaining TH-positive LC neurons were embedded already 3 weeks after viral vector delivery (Fig. 6d). Abundant direct physical contacts between TH-positive LC neurons and astro- and microglia could be resolved. In addition, numerous LC cells appeared to be nearly completely engulfed by microglial processes (Fig. 6d, arrows). In contrast, overexpression of Luc did not lead to any significant increase of astro- or microglia intensity values (Fig. 6a-d). Besides the interaction of astro- and microglia with LC neurons, we also observed direct physical contacts between astrocytes and microglial cells (Fig. 6e, arrow).
To underline our hypothesis that the degree of aSYN-induced pathology is closely associated with the degree of microgliosis, we correlated the microglial intensity values with the percentage of LC neurodegeneration (Fig. 6f, g). This revealed a correlation coefficient of r = 0.80 (p < 0.05) for A53T-aSYN, whereas for the Luc overexpressing animals no significant correlation was found (r = 0.09, p > 0.05).
Extensive transport of human A53T-aSYN to efferent brain regions
After investigating the local effects of A53T-aSYN overexpression, we addressed the question whether the aSYN pathology can propagate to anatomically connected brain regions. A variety of studies using overexpression of rAAV-aSYN or injection of preformed aSYN fibrils (PFF’s) have described transport or spread of aSYN to anatomically connected brain regions [35, 52, 54, 70, 77, 91]. To investigate the propagation of human A53T-aSYN after inducing the α-synucleinopathy in LC neuronal somata, we stained predetermined brain sections against human aSYN (Syn211) or Luc and rated the occurrence of aSYN- or Luc-positive axons or cell bodies (Table 2). While overexpression of Luc resulted in a staining pattern, which was limited to the injection site and absent in distant brain regions, we observed aSYN signal in a high number of brain regions in A53T-aSYN injected mice (Fig. 7). One week after injection of rAAV-A53T-aSYN in the right LC region, abundant aSYN-positive axons were observed in various brain regions which are known output regions of LC neurons . The human aSYN signal was solely axonal and no aSYN-positive cell bodies were detected. Regions showing the strongest aSYN signal included the main olfactory bulb, lateral septal nucleus, diagonal band nucleus, bed nuclei of the stria terminalis, central amygdalar nucleus, periaqueductal gray, midbrain reticular nucleus, substantia nigra (SN) pars compacta and the ventral tegmental area (Table 2). We counted 36 brain regions, which contained human aSYN-positive axons after one week, indicating that human A53T-aSYN was transported rapidly along the axons towards the synaptic terminals in an anterograde direction. Despite the increase of axonal aSYN signal, no aSYN-positive cell bodies were detected outside of the LC region at any investigated time point, arguing against the hypothesis that human A53T-aSYN is released in LC output regions and taken up by synaptically connected cells in the short time frame of 9 weeks. This is highlighted by the finding that staining against p-aSYN revealed no signs of phosphorylation or aggregation of endogenous aSYN in distant brain regions after 9 weeks whereas the axons containing human (non-phosphorylated) A53T-aSYN stained positive for TH (Fig. 8c).
No substantia nigra (SN) cell loss after 9 weeks of human A53T-aSYN overexpression in LC neurons
Already after 1 week of A53T-aSYN overexpression in LC neurons, human aSYN positive axons passing by DA SN neurons could be detected. After 9 weeks, SN neurons were densely surrounded by aSYN containing axons (Fig. 8a) but no human aSYN signal was observed in the somata of SN cells. Stereological quantification of TH-positive SN neurons (Fig. 8b) revealed no significant difference of TH-immunoreactive neurons between A53T-aSYN compared to Luc overexpressing mice neither for the left nor for the right SN (One-way ANOVA; p > 0.05). This result points out that LC degeneration, in combination with profound local axonal aSYN accumulation was not sufficient to induce degeneration of DA SN neurons within the relatively short period of 9 weeks.
Degeneration of the LC noradrenergic system is a key event during PD pathogenesis in the prodromal phase of the disease. In this study, we present the first targeted LC α-synucleinopathy mouse model, which replicated cardinal features of human PD pathology. We have designed our rAAV vector-based overexpression model to generate robust and rapid induction of aSYN pathology, including phosphorylation and aggregation of aSYN, noradrenergic neurodegeneration, development of dystrophic axon morphology, signs of proteasomal and lysosomal dysfunction and prominent neuron-glial interactions. Furthermore, the herein characterized aSYN transport pattern allows investigating the effects of aSYN-induced LC neurodegeneration on anatomically connected LC output structures.
Progressive S129 phosphorylation and formation of PK-resistant aSYN-positive aggregates
Phosphorylation of aSYN at amino acid S129 is a dominant pathological modification of aSYN  since approximately 90% of aSYN in human Lewy bodies is phosphorylated at this position, whereas only 4% of soluble aSYN exhibits this posttranslational modification . In PD animal models, phosphorylation at S129 is used as a key marker to investigate an induced α-synucleinopathy and its occurrence has often been interpreted as formation of aSYN aggregates [10, 52, 65, 72, 87]. In our current study, we show abundant and over time increasing S129-phosphorylation of aSYN in the cytoplasm and nucleus of LC cells (Fig. 3a, d). Previous studies have pointed out that aSYN has different cellular localizations. Beside the presynaptic and cytoplasmic localization, a nuclear occurrence of aSYN is known . Nuclear p-aSYN has been observed in previous studies where aSYN was overexpressed [30, 96] and it could be shown that nuclear aSYN interacts with histone molecules. It was even suggested that the S129-phosphorylation may play an important role for the nuclear translocation of aSYN . To confirm that phosphorylation of aSYN was accompanied by formation of high molecular weight aSYN aggregates we performed PK digestion experiments that revealed small circular aSYN positive inclusion bodies restricted to the injection site (Fig. 4c). Our model thereby reproduces a key feature of the LC pathology observed in human PD patients. Importantly, since PK digestion led to the destruction of all soluble proteins it did not allow us to investigate if the developing aSYN-positive inclusions are located in neurons or glial cells. The observed discrepancy between a high amount of p-aSYN-positive cells and a relatively limited number of aSYN-positive PK-resistant inclusions raises the question whether aSYN S129-phosphorylation can solely be used as a sufficient marker for aSYN aggregation. Our data indicate that S129-phosphorylation is an important indicator for aSYN pathology, but immunohistochemistry for other aggregation markers should be added to confirm the occurrence of aSYN aggregates [69, 90].
Formation of p62- and Ubi-1-positive proteinaceous inclusions in microglia
Additional markers, which are also commonly accepted to investigate protein aggregation and simultaneously serve as indicators for dysfunction of the proteasomal or lysosomal protein degradation system include Ubi-1 and p62 [33, 47]. Based on previous reports, which showed close co-localization of p-aSYN and Ubi-1 or p62 [54, 74], we expected to find overlap of these markers in our model. But notably, all p62 and Ubi-1 aggregates were located next to p-aSYN positive LC cells (Fig. 4a). Co-staining p62 and Ubi-1 with different glial and neuronal markers revealed that the p62 and Ubi-1 inclusions were located in IbA1-positive microglial cells (Fig. 5d, e). Further, we also show that microglia exhibited human aSYN, probably as a result of local aSYN uptake or phagocytosis of aSYN containing cellular debris. (Fig. 5f). The possibility that the microglial cells were transduced by rAAV1/2-A53T seems to be unlikely, since the used rAAV1/2 vector possesses a high neuronal tropism  and triple stainings for IbA1 (microglia), GFAP (astroglia) and aSYN revealed no aSYN-immunoreactivity 3 days after viral vector delivery within micro- or astroglial cells. Despite this, we cannot completely exclude the possibility of microglia transduction by the initial injection of rAAV1/2-A53T. Deposition of internalized aSYN aggregates in microglia has already been observed in vitro , but our study represents (to our knowledge) the first in vivo evidence of inclusion formation in microglial cells. We hypothesize that these p62- und Ubi-1-positive aggregates develop de novo in microglial cells possibly because of massive human aSYN uptake, which exceeds the lysosomal degradation capacities and leads to protein aggregation.
Currently we can only speculate why p62 and Ubi-1 reactivity was observed in microglia but absent in LC neurons. Previous studies have shown that p62-positive inclusions co-localize with Ubi-1 not only in neuronal but also in glial cells in neurodegenerative diseases including Alzheimer’s disease, dementia with Lewy bodies and PD . Furthermore, it has been shown that microglia rapidly internalize aSYN thereby representing the most efficient scavengers of neuronal released aSYN [48, 71]. By clearing aSYN, microglia might actively delay accumulation of aSYN and maturation of aSYN aggregates in LC neurons. One could hypothesize that in our model aSYN is rapidly released from LC neurons and taken up by microglia, which in turn leads to microglial but not neuronal accumulation of p62 und Ubi-1 aggregates. A longer duration of the experiment may clarify the question, whether Ubi-1- and p62-positive inclusions might also develop in LC neurons.
Reactive astro- and microglia and their implication in aSYN-induced LC pathology
Another key aspect in several animal models in which aSYN was injected or overexpressed [87, 88, 100] is the profound involvement of reactive astro- and microgliosis during the development of the aSYN pathology. It has been shown that activated microglial cells, besides their implication in clearing aSYN, are able to trigger the release of inflammatory cytokines and accelerate the production of reactive oxygen species, thereby likely contributing to the process of neurodegeneration [32, 42, 100]. In our model, LC cells were surrounded by a massive network of astro- and microglia already after 3 weeks of aSYN overexpression, with many microglial cells almost completely engulfing the surviving LC neurons (Fig. 6d, arrows). This early induction of microgliosis (Fig. 6c) is in line with previous findings where microgliosis even preceded the onset of neurodegeneration [4, 13]. Furthermore, we observed a strong correlation between the increase of microglial signal and LC cell loss (Fig. 6g), implying the conclusion that reactive microglial cells are important modulators of aSYN-induced toxicity not only in the dopaminergic SN but also in the noradrenergic LC. Microgliosis was accompanied by severe and progressively increasing astrogliosis. Reactive astrocytes surrounded and partially engulfed LC neurons. Furthermore, they formed direct physical contacts with reactive microglia (Fig. 6e, arrow) and exhibited clear signal for human aSYN (Fig. 5g). Importantly, reactive astrocytes can also take part in clearing aSYN by endocytosis and degradation in their lysosomal system [50, 76]. Furthermore, they interact closely with microglia and release pro- and anti-inflammatory molecules [18, 57]. Our LC model exemplifies this close interdependency between neurons, micro- and astroglia. We show that glial cells are highly involved in the process of aSYN degradation and that glial dysfunction or failure could be a factor of PD progression. However, it should also be considered that the LC itself plays a central role in decreasing neuroinflammation . Noradrenaline is able to suppress the expression of pro-inflammatory cytokines in glial cells while simultaneously elevating the expression of anti-inflammatory markers [19, 59]. Hence, it is reasonable to assume that loss of LC neurons additionally increases the neuroinflammatory response and contributes to the progressive increase of micro- and astroglial activity seen in our model.
Anterograde axonal transport of aSYN to LC output regions
To slow or prevent the progression of PD, it is essential to investigate if and how the α-synucleinopathy propagates within the brain. Recent evidence [36, 45, 52, 54, 70] suggests that toxic aSYN species formed in a small number of cells can spread trans-synaptically to distant but anatomically connected brain regions where they act as seeds to trigger the formation of insoluble aSYN aggregates [29, 54]. Furthermore, cell culture experiments have demonstrated that aSYN can be taken up by cells and transported in both the retrograde and anterograde direction [15, 23, 94]. The noradrenergic LC has a broad input-output connectome [82, 85] making this brain region suitable to investigate trans-neuronal spread. Moreover, Iba and colleagues  have demonstrated in a tauopathy model that injections of synthetic tau fibrils were able to induce tau pathology in LC neurons which then propagated to LC afferents and efferents. To investigate if this also translates into our LC aSYN overexpression model we systematically analyzed and scored the aSYN pathology after 1, 3, 6 and 9 weeks (Fig. 7, Table 2). Our results indicate that the overexpressed human A53T-aSYN, once produced in the cytoplasm of LC neurons, is only transported in the anterograde direction towards the synaptic terminals, as abundant aSYN-positive axons and terminals in efferent LC regions co-stained for TH (Fig. 7, Fig. 8c, Table 2). The broad LC output connectome  likely explains this high amount of aSYN-positive axons in distant brain regions of the ipsilateral but also contralateral hemisphere. The mild aSYN pathology of the contralateral (non-injected) side can be explained by LC projections crossing the midline and innervating brain structures of the contralateral hemisphere . In contrast to the profound axonal aSYN immunoreactivity, we found no aSYN-positive cell bodies outside of the LC region, arguing against trans-neuronal spread of aSYN in the relatively short time frame of 9 weeks. The absence of Luc-positive axons in LC output regions might be explained on one hand by protein size (Luc 62 kDa vs. aSYN 15 kDa) and on the other hand by the naturally presynaptic localization of aSYN [7, 89]. We therefore conclude that the aggregation prone aSYN species created by overexpression of human A53T-aSYN in the LC region are not transferred to other neuronal populations within the investigated 9 weeks. A longer time period and subsequently higher aSYN burden in the LC system may be necessary to enable such a transfer at later time points. This is in line with the finding that despite the severe degree of axonal aSYN accumulation in the SN region after 9 weeks of A53T-aSYN overexpression in the LC region, no statistically significant SN neurodegeneration was observed (Fig. 8).
Open questions and limitations
In this study, we have decided to overexpress human mutant A53T-aSYN by injection of a previously well-established rAAV vector. The vector used in this study has proven effective in inducing progressive neurodegeneration of SN neurons by several groups in several PD animal models [28, 34, 38, 43, 44]. In this context, it would be of relevance to investigate whether overexpression of wild-type aSYN in the LC would have led to a different histopathological phenotype. Considering the lower rate of β-sheet and fibril formation of wild-type aSYN compared to the A53T-aSYN variant [14, 51], one could hypothesize that overexpression of wild-type aSYN might lead to milder histopathological alterations. However, this has to be demonstrated in the LC model in a further study. For this initial study we have focused on a relatively short time frame of up to 9 weeks which allowed us to characterize the initial, local and time-dependent histopathological alterations of LC neurons caused by A53T-aSYN. Since 9 weeks is likely too short to observe the full neuropathology, a future study containing longer observation times of up to 52 weeks or even longer would be suggested. This would allow to further investigate whether trans-synaptic spread of aSYN and subsequent degeneration of dopaminergic SN neurons occur at a later time-point. As our study primarily aims to address the histopathological consequences of A53T-aSYN overexpression in LC neurons, we have not carried out a behavioral assessment. Nevertheless, the model would benefit from a thoroughly carried out behavioral characterization, including sleep recordings covering the possible occurrence of any non-motor or subtle motor symptoms.
In a time, in which on one hand the clinical research focus shifts away from the neurodegeneration of the dopaminergic nigrostriatal pathway towards the prodromal stages of PD and on the other hand the first potentially disease modifying therapies enter clinical testing , animal models mimicking the prodromal phase of PD are needed. In this study, we have reproduced cardinal histopathological features of the human LC PD-pathology, delineated the time-course of noradrenergic neurodegeneration and characterized robust histological markers, which are sufficient to assess the pathological changes in a quantitative and qualitative way. Taken together, this animal model may contribute to the research on the pathophysiology of the prodromal stage of PD. Further studies with longer observation times and additional characterization (e.g. behavioral assessment, biochemical analyses) are required to determine whether the herein presented model will prove helpful in the development and testing of disease-modifying therapy.
Phosphate buffered saline
Recombinant adeno-associated viral
REM sleep behavior disorder
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281(40):29739–29752. https://doi.org/10.1074/jbc.M600933200
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28:403–450. https://doi.org/10.1146/annurev.neuro.28.061604.135709
Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M (2012) Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 208:85–96. https://doi.org/10.1016/j.neuroscience.2012.02.004
Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL et al (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119(6):689–702. https://doi.org/10.1007/s00401-010-0664-3
Benarroch EE (2017) Locus coeruleus. Cell Tissue Res. https://doi.org/10.1007/s00441-017-2649-1
Bendor JT, Logan TP, Edwards RH (2013) The function of alpha-synuclein. Neuron 79(6):1044–1066. https://doi.org/10.1016/j.neuron.2013.09.004
Berridge CW, Waterhouse BD (2003) The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 42(1):33–84. https://doi.org/10.1016/S0165-0173(03)00143-7
Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA (1994) Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668(1–2):261–265. https://doi.org/10.1016/0006-8993(94)90534-7
Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N et al (2015) Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun 3:46. https://doi.org/10.1186/s40478-015-0222-2
Braak H, Del Tredici K, Rüb U, Vos D, Rob AI, Steur J, Ernst NH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24(2):197–211
Cersosimo MG, Benarroch EE (2012) Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis 46(3):559–564. https://doi.org/10.1016/j.nbd.2011.10.014
Chung CY, Koprich JB, Siddiqi H, Isacson O (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29(11):3365–3373. https://doi.org/10.1523/JNEUROSCI.5427-08.2009
Coskuner O, Wise-Scira O (2013) Structures and free energy landscapes of the A53T mutant-type alpha-synuclein protein and impact of A53T mutation on the structures of the wild-type alpha-synuclein protein with dynamics. ACS Chem Neurosci 4(7):1101–1113. https://doi.org/10.1021/cn400041j
Desplats P, Lee H-J, Bae E-J, Patrick C, Rockenstein E, Crews L et al (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106(31):13010–13015. https://doi.org/10.1073/pnas.0903691106
Doppler K, Jentschke H-M, Schulmeyer L, Vadasz D, Janzen A, Luster M et al (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. Acta Neuropathol 133(4):535–545. https://doi.org/10.1007/s00401-017-1684-z
Espay AJ, LeWitt PA, Kaufmann H (2014) Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord 29(14):1710–1719. https://doi.org/10.1002/mds.26048
Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28(3):138–145. https://doi.org/10.1016/j.it.2007.01.005
Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E (2002) Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 41(5):357–365
Feinstein DL, Kalinin S, Braun D (2016) Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J Neurochem 139(Suppl 2):154–178. https://doi.org/10.1111/jnc.13447
Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E et al (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 61(12):991–1001. https://doi.org/10.1002/syn.20456
Fornai F, Torracca MT, Bassi L, D'Errigo DA, Scalori V, Corsini GU (1996) Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res 735(2):349–353
Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y et al (2012) Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 72(4):517–524. https://doi.org/10.1002/ana.23747
Fu Y, Yuan Y, Halliday G, Rusznak Z, Watson C, Paxinos G (2012) A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct Funct 217(2):591–612. https://doi.org/10.1007/s00429-011-0349-2
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006) In vivo imaging of microglial activation with 11C(R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21(2):404–412. https://doi.org/10.1016/j.nbd.2005.08.002
Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 24(6):655–668. https://doi.org/10.1016/S0149-7634(00)00028-2
Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguere N, Barber JHM et al (2017) Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant alpha-synuclein rat model of parkinsonism. Neurobiol Dis 106:133–146. https://doi.org/10.1016/j.nbd.2017.06.009
Goedert M (2015) NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349(6248): 1255555. https://doi.org/10.1126/science.1255555
Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA et al (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42(28):8465–8471. https://doi.org/10.1021/bi0341152
Goldman JG, Postuma R (2014) Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 27(4):434–441. https://doi.org/10.1097/WCO.0000000000000112
Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR et al (2013) MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33(23):9592–9600. https://doi.org/10.1523/JNEUROSCI.5610-12.2013
Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM-Y et al (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277(50):49071–49076. https://doi.org/10.1074/jbc.M208046200
He Q, Koprich JB, Wang Y, Yu W-B, Xiao B-G, Brotchie JM et al (2015) Treatment with Trehalose prevents behavioral and neurochemical deficits produced in an AAV α-Synuclein rat model of Parkinson's disease. Mol Neurobiol. https://doi.org/10.1007/s12035-015-9173-7
Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OMA et al (2016) Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain 139(3):856–870. https://doi.org/10.1093/brain/awv376
Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T et al (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128(6):805–820. https://doi.org/10.1007/s00401-014-1343-6
Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM-Y (2015) Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta Neuropathol 130(3):349–362. https://doi.org/10.1007/s00401-015-1458-4
Ip CW, Klaus L-C, Karikari AA, Visanji NP, Brotchie JM, Lang AE et al (2017) AAV1/2-induced overexpression of A53T-alpha-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathol Commun 5(1):11. https://doi.org/10.1186/s40478-017-0416-x
Jones BE, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res 127(1):25–53
Kalia LV, Lang AE (2015) Parkinson's disease. Lancet 386(9996):896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Kilbourn MR, Sherman P, Abbott LC (1998) Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering. Synapse 30(2):205–210. https://doi.org/10.1002/(SICI)1098-2396(199810)30:2<205:AID-SYN10>3.0.CO;2-0
Kim C, Ho D-H, Suk J-E, You S, Michael S, Kang J et al (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4:1562. https://doi.org/10.1038/ncomms2534
Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM (2011) Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One 6(3):e17698. https://doi.org/10.1371/journal.pone.0017698
Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol Neurodegener 5:43. https://doi.org/10.1186/1750-1326-5-43
Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB (2008) Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 23(16):2303–2306. https://doi.org/10.1002/mds.22369
Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D et al (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56(10):1355–1362
Kuusisto E, Salminen A, Alafuzoff I (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12(10):2085–2090
Lee H-J, Suk J-E, Bae E-J, Lee J-H, Paik SR, Lee S-J (2008) Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 40(9):1835–1849. https://doi.org/10.1016/j.biocel.2008.01.017
Lee H-J, Suk J-E, Bae E-J, Lee S-J (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372(3):423–428. https://doi.org/10.1016/j.bbrc.2008.05.045
Lee H-J, Suk J-E, Patrick C, Bae E-J, Cho J-H, Rho S et al (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285(12):9262–9272. https://doi.org/10.1074/jbc.M109.081125
Li J, Uversky VN, Fink AL (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40(38):11604–11613
Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ et al (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949–953. https://doi.org/10.1126/science.1227157
Mahlknecht P, Seppi K, Poewe W (2015) The concept of prodromal Parkinson's disease. J Parkinsons Dis 5(4):681–697. https://doi.org/10.3233/JPD-150685
Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H et al (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136(Pt 4):1128–1138. https://doi.org/10.1093/brain/awt037
Matschke LA, Bertoune M, Roeper J, Snutch TP, Oertel WH, Rinné S et al (2015) A concerted action of L- and T-type ca(2+) channels regulates locus coeruleus pacemaking. Mol Cell Neurosci 68:293–302. https://doi.org/10.1016/j.mcn.2015.08.012
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38(8):1285–1291
McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23(4):474–483. https://doi.org/10.1002/mds.21751
McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA et al (2011) Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 1373:240–252. https://doi.org/10.1016/j.brainres.2010.12.015
Mori K, Ozaki E, Zhang B, Yang L, Yokoyama A, Takeda I et al (2002) Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology 43(6):1026–1034
Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139(Suppl 1):325–337. https://doi.org/10.1111/jnc.13750
Oertel WH (2017) Recent advances in treating Parkinson's disease. F1000Res 6: 260. Doi: https://doi.org/10.12688/f1000research.10100.1
Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128(Pt 11):2665–2674. https://doi.org/10.1093/brain/awh625
Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T et al (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57(2):168–175. https://doi.org/10.1002/ana.20338
Oueslati A (2016) Implication of alpha-Synuclein phosphorylation at S129 in Synucleinopathies: what have we learned in the last decade? J Parkinsons Dis 6(1):39–51. https://doi.org/10.3233/JPD-160779
Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ et al (2015) Intrastriatal injection of pre-formed mouse alpha-synuclein fibrils into rats triggers alpha-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185–199. https://doi.org/10.1016/j.nbd.2015.06.003
Paxinos G, Franklin KBJ (2013) Paxinos and Franklin's the mouse brain in stereotaxic coordinates, 4th edn. Elsevier Acad. Press, Amsterdam
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045–2047
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
Recasens A, Ulusoy A, Kahle PJ, Di Monte DA, Dehay B (2017) In vivo models of alpha-synuclein transmission and propagation. Cell Tissue Res. https://doi.org/10.1007/s00441-017-2730-9
Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ et al (2018) Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 135(1):65–83. https://doi.org/10.1007/s00401-017-1792-9
Rey NL, Petit GH, Bousset L, Melki R, Brundin P (2013) Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126(4):555–573. https://doi.org/10.1007/s00401-013-1160-3
Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ et al (2016) Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 213(9):1759–1778. https://doi.org/10.1084/jem.20160368
Richter-Landsberg C, Leyk J (2013) Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathol 126(6):793–807. https://doi.org/10.1007/s00401-013-1158-x
Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S et al (2011) Neuropathology in mice expressing mouse alpha-synuclein. PLoS One 6(9):e24834. https://doi.org/10.1371/journal.pone.0024834
Robertson SD, Plummer NW, de Marchena J, Jensen P (2013) Developmental origins of central norepinephrine neuron diversity. Nat Neurosci 16(8):1016–1023. https://doi.org/10.1038/nn.3458
Rostami J, Holmqvist S, Lindstrom V, Sigvardson J, Westermark GT, Ingelsson M et al (2017) Human astrocytes transfer aggregated alpha-Synuclein via tunneling nanotubes. J Neurosci 37(49):11835–11853. https://doi.org/10.1523/JNEUROSCI.0983-17.2017
Rusconi R, Ulusoy A, Aboutalebi H, Di Monte DA (2018) Long-lasting pathological consequences of overexpression-induced alpha-synuclein spreading in the rat brain. Aging Cell. https://doi.org/10.1111/acel.12727
Sanchez-Padilla J, Guzman JN, Ilijic E, Kondapalli J, Galtieri DJ, Yang B et al (2014) Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat Neurosci 17(6):832–840. https://doi.org/10.1038/nn.3717
Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(8):509. https://doi.org/10.1038/nrn.2017.91
Schell H, Hasegawa T, Neumann M, Kahle PJ (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160(4):796–804. https://doi.org/10.1016/j.neuroscience.2009.03.002
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. https://doi.org/10.1038/nmeth.2019
Schwarz LA, Miyamichi K, Gao XJ, Beier KT, Weissbourd B, DeLoach KE et al (2015) Viral-genetic tracing of the input–output organization of a central noradrenaline circuit. Nature 524(7563):88–92. https://doi.org/10.1038/nature14600
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840. https://doi.org/10.1038/42166
Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH et al (2005) Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128(Pt 1):126–137. https://doi.org/10.1093/brain/awh322
Szabadi E (2013) Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol (Oxford) 27(8):659–693. https://doi.org/10.1177/0269881113490326
Taschenberger G, Garrido M, Tereshchenko Y, Bahr M, Zweckstetter M, Kugler S (2012) Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 123(5):671–683. https://doi.org/10.1007/s00401-011-0926-8
Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC et al (2017) Modeling Parkinson's disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. Proc Natl Acad Sci U S A 114(39):E8284–E8293. https://doi.org/10.1073/pnas.1710442114
Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149–1158. https://doi.org/10.1097/NEN.0b013e31818e5e99
Thorne N, Inglese J, Auld DS (2010) Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol 17(6):646–657. https://doi.org/10.1016/j.chembiol.2010.05.012
Uchihara T, Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131(1):49–73. https://doi.org/10.1007/s00401-015-1485-1
Ulusoy A, Phillips RJ, Helwig M, Klinkenberg M, Powley TL, Di Monte DA (2017) Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections. Acta Neuropathol 133(3):381–393. https://doi.org/10.1007/s00401-016-1661-y
Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L (2011) Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 10(11):1015–1025. https://doi.org/10.1016/S1474-4422(11)70213-7
Vermeiren Y, de Deyn PP (2017) Targeting the norepinephrinergic system in Parkinson's disease and related disorders: the locus coeruleus story. Neurochem Int 102:22–32. https://doi.org/10.1016/j.neuint.2016.11.009
Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57–71. https://doi.org/10.1016/j.neuron.2011.08.033
Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38(Suppl 2):2–7
Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M et al (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85(8):1819–1825. https://doi.org/10.1002/jnr.21310
Weinshenker D (2018) Long road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. https://doi.org/10.1016/j.tins.2018.01.010
Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91(2):451–461. https://doi.org/10.1111/j.1471-4159.2004.02728.x
Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60(3):337–341
Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19(6):533–542. https://doi.org/10.1096/fj.04-2751com
We thank Sabine Anfimov and Christine Höft for technical assistance regarding the experiments. We also gratefully acknowledge the Core Facility Cellular Imaging of Philipps University-Marburg for the use of the Leica TCS SP8 confocal microscope and Zeiss Axio Observer Z1 spinning disc microscope. We thank Katrin Roth for the assistance with microscopy. WHO is a Hertie-Senior-Research Professor supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany. LAM and WHC have received a grant from the intramural research fund of the Rhön-Klinikum Aktiengesellschaft. BL is a fellow of Deutscher Akademischer Austauschdienst.
WHO is supported by the Charitable Hertie Foundation, Frankfurt/Main, Germany. LAM and WHC have received a grant from the Rhön-Klinikum Aktiengesellschaft. BL is a fellow of DAAD.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Ethics approval and consent to participate
All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All animal experiments were approved by the local authorities (Regierungspräsidium Giessen, Germany V54–19 c 20 15 h 01 MR 20/15 Nr. 66/2015).
The authors declare no competing financial interests. JBK and JMB have equity stakes in, and have received consultancy fees from, Atuka Inc., outside of the submitted work. WHO received personal fees for educational talks and/or consultancy, outside of the submitted work, from Abbvie, Adamas, Bristol-Myer-Squibb, Desitin, Mundipharma, Neuropore, Novartis, Roche and UCB Pharma and grants from the Deutsche Forschungsgemeinschaft, the International Parkinson-Fonds The Netherlands, the Michael J. Fox Foundation, USA, the National Research Fond Luxembourg and from Novartis Pharma, Germany.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Lina Anita Matschke and Wolfgang Hermann Oertel are shared senior authors.
About this article
- Parkinson’s disease
- Locus coeruleus
- Adeno-associated viral vectors
- Prodromal mouse model
- Microglia, noradrenergic neurons